Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Shares Outstanding (Weighted Average) (2016 - 2025)

Cytosorbents (CTSO) has disclosed Shares Outstanding (Weighted Average) for 14 consecutive years, with $62.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 15.48% year-over-year to $62.8 million, compared with a TTM value of $62.8 million through Sep 2025, up 15.48%, and an annual FY2024 reading of $54.4 million, up 21.9% over the prior year.
  • Shares Outstanding (Weighted Average) was $62.8 million for Q3 2025 at Cytosorbents, up from $61.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $62.8 million in Q3 2025 and bottomed at $43.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $48.8 million, with a median of $44.0 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) grew 27.25% in 2021, then grew 0.43% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $43.4 million in 2021, then increased by 0.49% to $43.6 million in 2022, then rose by 2.49% to $44.7 million in 2023, then rose by 21.9% to $54.4 million in 2024, then rose by 15.28% to $62.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CTSO at $62.8 million in Q3 2025, $61.7 million in Q2 2025, and $60.7 million in Q1 2025.